Primary Aldosteronism Market Overview
The Primary Aldosteronism Market is expanding as awareness of primary aldosteronism and its connection to hypertension and cardiovascular complications increases. Greater recognition of the condition is encouraging earlier diagnosis, while advances in diagnostic technologies and therapeutic options are creating new opportunities for market participants. The market was valued at USD 1.86 billion in 2024 and USD 1.9422 billion in 2025, and is projected to reach USD 3.0 billion by 2035, registering a CAGR of 4.4% from 2026 to 2035.
The report was published in June 2026 and identifies North America as the leading regional market, valued at USD 800 million in 2024 and projected to reach USD 1.2 billion by 2035. Biochemical Testing is the leading diagnosis method, with a market value of USD 800 million in 2024 and an expected value of USD 1.2 billion by 2035. Medication is also anticipated to remain the leading treatment type as pharmaceutical innovation and the development of new therapies support market expansion.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/reports/primary-aldosteronism-market
Key players driving innovation and competitiveness in the Primary Aldosteronism Market include:
AstraZeneca
Teva Pharmaceuticals
Lexicon Pharmaceuticals
Gilead Sciences
AbbVie
Verily Life Sciences
Sanofi
Merck
Amgen
Alnylam Pharmaceuticals
Bristol Myers Squibb
Pfizer
Eisai
Novartis
Johnson & Johnson
Bayer
Market growth is being supported by increasing awareness and diagnosis of primary aldosteronism, particularly as healthcare professionals recognize the condition as an important cause of secondary hypertension. Improved screening guidelines, greater patient awareness, and increasing identification of previously undiagnosed cases are expected to strengthen demand for diagnostic and treatment solutions.
Technological advancements are transforming the diagnostic landscape. Non-invasive testing, improved imaging techniques, genetic testing, and artificial intelligence-enabled diagnostic tools can support earlier and more accurate identification of the disorder. At the same time, pharmaceutical companies are investing in novel mineralocorticoid receptor antagonists and other targeted therapies, creating opportunities for more personalized treatment approaches.
The market is segmented by diagnosis method into Biochemical Testing, Imaging Techniques, Genetic Testing, and Adrenal Vein Sampling. Biochemical Testing remains the leading segment because of its role in assessing hormonal levels. By treatment type, the market includes Medication, Surgery, and Lifestyle Changes, with medication maintaining a strong position. End users include Hospitals, Homecare, Diagnostic Laboratories, and Specialty Clinics, while patient types comprise Adult Males, Adult Females, and Pediatric Patients.
Recent Developments and Market Trends:
Growing awareness of primary aldosteronism is supporting higher screening and diagnosis rates among patients with hypertension.
AI-enabled diagnostic tools are emerging as an opportunity to improve early detection and treatment selection.
Genetic testing and personalized medicine are gaining importance as healthcare providers seek more tailored treatment strategies.
Novel mineralocorticoid receptor antagonists are expanding the pipeline of potential therapeutic options.
Asia Pacific is expected to offer significant growth opportunities as healthcare infrastructure, awareness, and access to diagnosis improve.
Reasons to Buy the Report:
Understand the global market size, growth trajectory, and forecast through 2035.
Analyze major diagnosis methods including biochemical, imaging, genetic, and adrenal vein sampling techniques.
Evaluate treatment opportunities across medication, surgery, and lifestyle changes.
Assess regional market dynamics and growth opportunities across North America, Europe, Asia Pacific, South America, and MEA.
Identify key companies, competitive strategies, market drivers, technological trends, and emerging opportunities.
Future Outlook:
The future outlook for the Primary Aldosteronism Market remains positive as growing recognition of the condition, rising hypertension prevalence, improved diagnostic capabilities, and advances in targeted therapies support continued market development. North America is expected to maintain its leadership, increasing from USD 800 million in 2024 to USD 1.2 billion by 2035, while Europe is expected to follow closely and Asia Pacific presents notable growth opportunities. Biochemical Testing is projected to remain the leading diagnosis method, while Medication is expected to maintain its strong position among treatment options. Increasing investment in genetic testing, AI-supported diagnostics, personalized medicine, and innovative therapeutic pipelines will further strengthen the market, supporting growth to USD 3.0 billion by 2035 at a CAGR of 4.4%.
